Safety & Efficacy of Nerve Rerouting to treat Neurogenic Bladder in Spina Bifida

安全

基本信息

项目摘要

DESCRIPTION (provided by applicant): Spina Bifida, a congenital defect of the spinal cord, causes nerve damage and a loss of sensation and muscle function below the waist resulting in bowel, bladder and sexual dysfunction. Patients cannot urinate or are constantly wet, and this continues throughout life causing major quality of life and health problems. Clean intermittent catheterization is usually needed to empty the bladder properly. Antimuscarinic medications are commonly required to alleviate high urinary tract pressures that can cause irreversible kidney damage, where dialysis or kidney transplant is the only way to sustain life. Dr. Xiao developed and is performing a novel procedure in China that connects a functioning, healthy lumbar spinal nerve root to the sacral nerve that controls the bladder. The end result is the creation of a new reflex where the bladder can be emptied by scratching or stimulating the skin supplied by that spinal nerve root. He has reported that in 92 SCI patients, 88% regained bladder control within one year after the nerve rerouting surgery and in 110 children with spina bifida, reported success in 87% at one year. However, in China rigorous follow up is challenging, therefore much is still unknown about the neurorecovery post surgery, complications and results occurring in the first year in particular, and the potential role that central nervous system remodeling may play in achieving successful outcomes. At Beaumont, a pilot study is underway on 9 spina bifida subjects, however no other center in the US is currently studying this technique. Our preliminary data are very promising, and with 9 subjects now 12 months post procedure, 7/9 subjects are voiding either voluntarily or by stimulating the new reflex mechanism. This project aims to expand upon our pilot experience to conduct a larger and more rigorous study to establish the safety and effectiveness of the proposed somatic-autonomic reflex pathway procedure in gaining bladder and bowel control in patients with spina bifida. Additionally, we will systemically evaluate and optimize frequency and location for excitation of the new somatic-autonomic reflex arc to a) gain more insight into the neurorecovery associated with nerve rerouting, and b) scientifically and systematically determine the ideal stimulation parameters to achieve best voiding results and make the somatic-autonomic reflex pathway rerouting most useful for the patients. Achieving the aims outlined in this proposal will help firmly establish the procedure as safe and effective, and revolutionize the treatment of bladder and bowel dysfunction in patients with spina bifida. PUBLIC HEALTH RELEVANCE: Spina Bifida, a congenital defect of the spinal cord, causes nerve damage resulting in bowel, bladder and sexual dysfunction. Dr. Xiao, in China, developed a new procedure to rewire the nerves affecting the bladder, and this project aims to scientifically establish the safety and effectiveness of the surgical procedure.
描述(由申请人提供):脊柱裂是一种脊髓先天性缺陷,会导致神经损伤以及腰部以下感觉和肌肉功能的丧失,从而导致肠道、膀胱和性功能障碍。患者无法排尿或经常尿湿,这种情况会持续一生,导致严重的生活质量和健康问题。通常需要清洁间歇导尿以正确排空膀胱。通常需要抗毒蕈碱药物来缓解高尿路压力,这种压力可能导致不可逆的肾脏损伤,而透析或肾移植是维持生命的唯一方法。肖医生开发并正在中国实施一种新颖的手术,该手术将功能正常、健康的腰椎神经根与控制膀胱的骶神经连接起来。最终结果是产生一种新的反射,通过抓挠或刺激由脊神经根供应的皮肤来排空膀胱。他报告说,在 92 名 SCI 患者中,88% 的人在神经改道手术后一年内恢复了膀胱控制,而在 110 名脊柱裂儿童中,87% 的人在一年内成功。然而,在中国,严格的随访具有挑战性,因此对于手术后的神经恢复、特别是第一年发生的并发症和结果,以及中枢神经系统重塑在实现成功结果中可能发挥的潜在作用,仍然有很多未知。在博蒙特,一项针对 9 名脊柱裂受试者的试点研究正在进行中,但目前美国没有其他中心正在研究这项技术。我们的初步数据非常有希望,9 名受试者在术后 12 个月后,7/9 的受试者要么自愿排尿,要么通过刺激新的反射机制排尿。该项目旨在扩展我们的试点经验,进行更大规模、更严格的研究,以确定所提出的躯体自主反射通路程序在脊柱裂患者获得膀胱和肠道控制方面的安全性和有效性。此外,我们将系统地评估和优化新的躯体自主反射弧的激发频率和位置,以a)更深入地了解与神经重新路由相关的神经恢复,b)科学、系统地确定理想的刺激参数,以实现最佳排尿效果,并使躯体自主反射通路重新路由对患者最有用。实现该提案中概述的目标将有助于牢固地确立该手术的安全性和有效性,并彻底改变脊柱裂患者膀胱和肠道功能障碍的治疗。公共卫生相关性:脊柱裂是一种脊髓先天性缺陷,会导致神经损伤,导致肠道、膀胱和性功能障碍。中国的肖医生开发了一种新的手术来重新连接影响膀胱的神经,该项目旨在科学地确定手术程序的安全性和有效性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH M PETERS其他文献

KENNETH M PETERS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH M PETERS', 18)}}的其他基金

Sacral neuromodulation for the management of chronic pelvic pain
骶神经调节治疗慢性盆腔疼痛
  • 批准号:
    10837385
  • 财政年份:
    2023
  • 资助金额:
    $ 46.24万
  • 项目类别:
Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina B
神经重新布线治疗 B 型脊柱神经源性膀胱的安全性和有效性
  • 批准号:
    7940871
  • 财政年份:
    2009
  • 资助金额:
    $ 46.24万
  • 项目类别:
Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina B
神经重新布线治疗 B 型脊柱神经源性膀胱的安全性和有效性
  • 批准号:
    7696321
  • 财政年份:
    2009
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    6794203
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    7036549
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    7251390
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    6682670
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    7235256
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
Beaumont Interstitial Cystitis Clinical Research Network
博蒙特间质性膀胱炎临床研究网络
  • 批准号:
    6882684
  • 财政年份:
    2003
  • 资助金额:
    $ 46.24万
  • 项目类别:
IMMUNE MEDIATORS IN INTERSTITIAL CYSTITIS
间质性膀胱炎中的免疫介质
  • 批准号:
    6178238
  • 财政年份:
    1999
  • 资助金额:
    $ 46.24万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 46.24万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 46.24万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 46.24万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 46.24万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 46.24万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 46.24万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 46.24万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 46.24万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 46.24万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 46.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了